“Long-Term Safety and Effectiveness of Adalimumab for Moderat-to-Severe Psoriasis: Results from the Eight-Year Interim Analysis of the ESPIRIT Registry” (2017) SKIN The Journal of Cutaneous Medicine, 1(3.1), p. s22. doi:10.25251/skin.1.supp.21.